When It Comes To Antibody Technology, Pfizer's On The Prowl
This article was originally published in The Pink Sheet Daily
Pfizer's latest partnership in the space is with Theraclone Sciences, a Seattle start-up with an antibody technology that uses human B cells.
You may also be interested in...
Pfizer aims to acquire rival Wyeth in a proposed deal valued at approximately $68 billion, broadening Pfizer's leadership position in the market by creating a drug powerhouse with combined sales of more than $71 billion, based on 2008 revenues
Firm hopes to use Haptogen’s technology to generate novel protein therapeutics that can be made orally bioavailable, VP-Biologic Technologies Projan tells “The Pink Sheet” DAILY.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.